

Anti-IL-3Ra/CD123 Antibody (Talacotuzumab)

Introduction

Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized CD123 neutralizing monoclonal antibody with a modified Fc structure. Talacotuzumab has KDs of 0.43 nM, 188 nM, 46 nM, and 16.8 nM for CD123, CD32b/c, CD16-158F, and CD16-158V, respectively. Talacotuzumab inhibits the binding of IL-3 to CD123, thereby antagonizing IL-3 signaling in target cells. Talacotuzumab mutates the Fc region to increase affinity for CD16 (FcγRIIIa), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab is highly effective in reducing leukemic cell growth in an acute myeloid leukemia (AML) xenograft mouse model in vivo.

Product parameters

Alternative Names	JNJ-56022473, CSL362
Target Accession	P26951
Target	IL-3Ra / CD123
CAS number	1826831-79-1
Molecular Weight	147.42 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Immobilized human IL 3Rα His at 2 ug/mL can bind Anti-IL-3Ra/CD123 Antibody (Talacotuzumab), EC50=0.003253 ug/mL.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 μM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice

Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.



Note

1. This product is for scientific research use only.



APExBIO Technology
www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

